Very good interview with Sam Herbert, President - World Courier, in American Pharmaceutical Review.   Sam describes the unprecedented complexity that cell and gene therapy companies are facing as they begin to commercialize their therapies.

 

 "Because the patient’s own body is part of the product—and therefore part of the manufacturing and supply chain processes—cell and gene therapy manufacturers face complexities that are orders of magnitude greater than many other specialty and orphan products."
Sam Herbert   President - World Courier

Read more here: